FSHB

Across TCGA pan-cancer cohorts, FSHB Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FSHB data layer compared with 12 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher FSHB Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated FSHB expression acts as an unfavorable survival marker, although some lineages such as SKCM and COAD show a favorable association.

SKCM, CHOL, and COAD are the cancer types where FSHB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.858	0.216	.012	10	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
COAD	DFS	Median	II,III,IV	1.000	0.421	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FSHB–SKCM (DFS)

Open the SKCM breakdown →